Results 61 to 70 of about 10,049 (144)
Safety Issues With the Use of Antimicrobials in Current Clinical Practice [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2015 Due to increased use of antibiotics in current clinical practice it is very important to evaluate all risks of antimicrobial therapy. Pharmacovigilance plays a vital role in ensuring that doctors, together with the patient, have enough information about ...
Kuzmina A.V. +3 more
doaj
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg +1 more
wiley +1 more source
Cyclooxygenase-2 inhibitors: promise or peril?
Mediators of Inflammation, 2002 The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized ...
Laurel J. Mengle-Gaw +1 more
doaj +1 more source
Beyond Blind Trust in Hospital Data Warehouses: Evaluating Real‐World Data Accountability
Learning Health Systems, Volume 10, Issue 4, October 2026.ABSTRACT Introduction The reliability of real‐world evidence (RWE) depends on data accuracy and secondary users' ability to evaluate how data are generated and transformed. Although recent frameworks emphasize provenance, transparency, and auditability, their practical assessment in routine hospital settings remains unclear.
Akemi Morohashi +6 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1083-1096, October 2026.In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus +8 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal +2 more
wiley +1 more source
Trends in the use of validated claims-based algorithms in Japanese post-marketing database studies
Frontiers in PharmacologyBackgroundIn pharmacoepidemiological research, misclassification is a concern with claims-based algorithms (also called computable phenotypes). Validating them is crucial, particularly within regulatory settings.
Chieko Ishiguro, Takahiro Nonaka
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 9, September 2026.ABSTRACT Dimethyl fumarate may rarely cause severe hepatocellular injury. In a 26‐year‐old woman, liver enzymes rose soon after treatment initiation, and biopsy supported DILI. Updated RUCAM assessment yielded 6, indicating probable causality, supported by dechallenge.
Ophir Lavon, Maram Salameh
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source